GILD - Gilead Sciences, Inc.
| Previous close | 74.44 |
| Open | 74.40 |
| Bid | 73.70 x 300 |
| Ask | 74.33 x 800 |
| Day's range | 73.18 - 74.42 |
| 52-week range | 63.76 - 89.54 |
| Volume | 4,229,088 |
| Avg. volume | 7,924,082 |
| Market cap | 96.094B |
| Beta | 1.35 |
| PE ratio (TTM) | 21.00 |
| EPS (TTM) | 3.51 |
| Earnings date | 1 May 2018 |
| Forward dividend & yield | 2.28 (3.03%) |
| Ex-dividend date | 2018-03-15 |
| 1y target est | 88.95 |
Market Realist•10 hours agoExploring the Financial Performance of Sarepta Therapeutics
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) generated revenues of $154.5 million in fiscal 2017 compared with $5.4 million in fiscal 2016. The substantial increase in revenues shows the increasing demand for the product.
- Forbes•11 hours ago
8%+ Dividends From My Favorite Sector Now
I want to show you a beaten-down sector that has a long history of crushing the market—and 4 funds that should be on your radar now.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research
The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research
- Barrons.com•yesterday
[$$] Big Buys in Alphabet, Facebook for Hot Hedge-Fund Manager
Antipodes is also quite contrarian. Antipodes is located Down Under, but its performance has been Up Above. The Antipodes Global Fund-Long Only, the Antipodes Global fund, and the Antipodes Asia fund all adopted new strategies on June 30, 2015, and since then, through the first quarter of 2018, they are up 44.9%, 42.4%, and 34.4%, respectively, in absolute performance.
- Zacks•2 days ago
Top Research Reports for IBM, McDonald's & Gilead
Top Research Reports for IBM, McDonald's & Gilead
- MarketWatch•2 days ago
Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
- Market Realist•2 days ago
Analysts’ Recommendations for Exelixis in April 2018
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
Market Realist•2 days agoGilead Sciences Expects Decline in Earnings in Fiscal 2018
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
Market Realist•3 days agoGilead Sciences May Witness Significant Drop in Revenues in 2018
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
Market Realist•3 days agoWhat Analysts Recommend for Gilead Sciences in April 2018
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
- Zacks•3 days ago
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Market Realist•3 days agoAbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
- Business Wire•4 days ago
Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Gilead Sciences, Inc. announced today that its first quarter 2018 financial results will be released on Tuesday, May 1, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2018 and provide a general business update.
Market Realist•4 days agoAbbVie’s Imbruvica in 4Q17 and Fiscal 2017
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
- Zacks•5 days ago
Gilead (GILD) Presents Encouraging Data on NASH Therapies
Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.
- Motley Fool•5 days ago
3 Growth Stocks for Successful Investors
Investing success can sometimes be achieved by looking beyond the obvious choices. Check out the growth potential of Shopify, Atara Bio, and Criteo.
- Market Realist•5 days ago
Johnson & Johnson’s Revenue Estimates for 1Q18
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
- Motley Fool•8 days ago
3 Top Healthcare Stocks to Buy in April
April could be the perfect time to pick up shares in these top healthcare stocks.
- Business Wire•8 days ago
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
More than 25 additional Gilead abstracts on NASH and other fibrotic liver diseases are also being presented, including data from predictive modeling studies using noninvasive tests for the diagnosis and monitoring of NASH that aim to reduce the need for liver biopsy.
- Business Wire•8 days ago
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Gilead Sciences, Inc. today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis , combining the apoptosis signal-regulating kinase 1 inhibitor selonsertib with either the Acetyl-CoA carboxylase inhibitor GS-0976 or the selective, non-steroidal Farnesoid X receptor agonist GS-9674.
- The Wall Street Journal•9 days ago
[$$] How Big Biotech Can Win Back Investors
Big biotech stocks are trading at their lowest valuations in years, but don’t underestimate their ability to turn things around quickly.
- Motley Fool•9 days ago
Why One Drug Flop Tanked Incyte's Stock
Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.
- CNBC•10 days ago
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
- Motley Fool•10 days ago
This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous
There's a new kid on the CAR-T block.
- Barrons.com•10 days ago
[$$] An S&P 500-Topping Advisor Dumps Its GE Stake
Mark Keller, chief executive and chief investment officer of Confluence Investment Management, focuses on conglomerates, so it’s not surprising that the advisor had held a large position in General Electric. What’s surprising is that Confluence, which is based in St. Louis, sold in the first quarter all 2.8 million GE (GE) shares that it had held at the end of 2017, according to regulatory filings. Elsewhere, Keller and Confluence, which managed $5.4 billion in U.S.-traded securities at the end of the first quarter, was in a mood for buying well-known names in the period.
